Reference [1]Altman B J, Stine Z E, Dang C V
At ObesityWeek on Sunday, Viking Therapeutics unveiled early data from the first-in-human study of its investigational oral obesity drug VK2735, touting strong weight loss in healthy adults and an encouraging safety profile.
No GLP-2 medication is approved for the indications GLP-1 medications cover
Therefore, Carnipure L-Carnitine is emerging as a key ingredient in exercise and recovery type formulations across the globe
Unlike currently approved therapies such as semaglutide and tirzepatide, retatrutide acts on three metabolic pathways, leading many obesity medicine experts to view it as a potential next-generation treatment for obesity and related metabolic conditions
Full body composition results are apparent at 3 months and continue post-cycle